ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
January 22, 2021 01:39 ET
|
Helsinn Healthcare S.A.
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Not intended for US media ...
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
January 12, 2021 03:30 ET
|
Helsinn Healthcare S.A.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss...
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor
December 07, 2020 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor Lugano,...
Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area
December 01, 2020 02:30 ET
|
Helsinn Healthcare S.A.
Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area Lugano, Switzerland, and Singapore,...
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI)
September 23, 2020 04:43 ET
|
Helsinn Healthcare S.A.
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI) Lugano, Switzerland,...
Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020
September 18, 2020 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and palonosetron) data at ESMO Virtual Congress 2020 - A Phase 3 study concludes that a simplified regimen of...
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US
August 20, 2020 09:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building...
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay
July 30, 2020 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay Biasca, Switzerland, July 30, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare...
3B Future Health Fund announces new investment in iOnctura
July 14, 2020 03:00 ET
|
Helsinn Healthcare S.A.
3B Future Health Fund announces new investment in iOnctura MONACO, PRINCIPALITY OF MONACO, July 14, 2020: 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today...
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
July 02, 2020 07:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss...